7,239 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by SYM FINANCIAL Corp

SYM FINANCIAL Corp purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 7,239 shares of the biotechnology company's stock, valued at approximately $267,000.

Other institutional investors have also recently made changes to their positions in the company. Coppell Advisory Solutions LLC acquired a new position in shares of Exelixis in the fourth quarter worth $25,000. Colonial Trust Co SC grew its stake in shares of Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 765 shares in the last quarter. Bartlett & CO. Wealth Management LLC acquired a new position in shares of Exelixis in the first quarter worth $37,000. Hurley Capital LLC acquired a new position in shares of Exelixis in the fourth quarter worth $68,000. Finally, True Wealth Design LLC grew its stake in shares of Exelixis by 222.3% in the fourth quarter. True Wealth Design LLC now owns 2,253 shares of the biotechnology company's stock worth $75,000 after acquiring an additional 1,554 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Insider Activity

In other news, EVP Patrick J. Haley sold 126,383 shares of Exelixis stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the completion of the sale, the executive vice president directly owned 446,459 shares in the company, valued at approximately $21,412,173.64. This trade represents a 22.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jeffrey Hessekiel sold 25,000 shares of Exelixis stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $46.18, for a total transaction of $1,154,500.00. Following the sale, the executive vice president owned 693,396 shares of the company's stock, valued at approximately $32,021,027.28. The trade was a 3.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 458,113 shares of company stock valued at $21,024,817 over the last ninety days. 2.82% of the stock is currently owned by company insiders.

Exelixis Stock Down 1.3%

NASDAQ EXEL traded down $0.61 during trading hours on Thursday, hitting $44.79. 2,188,526 shares of the stock were exchanged, compared to its average volume of 2,601,056. The company has a market cap of $12.21 billion, a price-to-earnings ratio of 20.36, a price-to-earnings-growth ratio of 0.91 and a beta of 0.28. Exelixis, Inc. has a 12-month low of $22.36 and a 12-month high of $49.62. The stock has a 50-day moving average of $43.46 and a 200 day moving average of $38.71.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Jefferies Financial Group set a $50.00 price target on shares of Exelixis and gave the stock a "buy" rating in a research note on Tuesday, June 24th. Benchmark reiterated a "neutral" rating on shares of Exelixis in a research note on Monday, June 23rd. Royal Bank Of Canada reiterated a "sector perform" rating and set a $50.00 target price (up previously from $45.00) on shares of Exelixis in a research note on Tuesday, July 8th. Citigroup boosted their target price on shares of Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. Finally, Truist Financial set a $56.00 target price on shares of Exelixis and gave the stock a "buy" rating in a research note on Tuesday, July 15th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.33.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.